7月1日，脑机接口概念延续强势，创新医疗2连板，塞力医疗涨停，翔宇医疗涨超5%，爱朋医疗、三博 脑科、伟思医疗等跟涨。 消息面上，中国首个脑机接口未来产业集聚区"脑智天地"在上海启动建设。另外，马斯克在脑机接口 Neuralink团队的发布会上表示，目前全球已经有七人植入了设备，通过"心灵感应"产品，他们重获跟物 理世界交互的能力，可以用大脑玩马里奥赛车、使命召唤，甚至可以控制机械臂写字。预计2026年让盲 人重获光明，2028年计划实现更广泛的人机融合应用。 国家药监局于6月20日审议通过《关于优化全生命周期监管支持高端医疗器械创新发展的举措》。其中 提到，加快发布医用外骨骼机器人、放射性核素成像设备等相关标准；积极筹建医用机器人、人工智能 医疗器械标准化技术委员会；加强增材制造用医用材料、脑机接口柔性电极、基因工程合成生物材料等 新型生物材料标准化研究。 东吴证券表示，侵入式技术的持续突破将推动消费和医疗康复市场提升对脑机接口技术的认知，非侵入 式脑机接口产品的商业化落地也有望加速。此外，前沿探索如生物计算机等领域的发展，也为脑机接口 技术的未来发展提供了更多可能性。浙商证券表示，脑科学如能取得重大进展， ...

Group 1 - A-shares market showed strong performance with all major indices rising, including Shanghai Composite Index up 0.59%, Shenzhen Component Index up 0.83%, and ChiNext Index up 1.35% on the last trading day of June [1][2][7] - The total market turnover reached 15,172 billion, with over 4,000 stocks rising, indicating a broad-based rally [1][7] - In the first half of the year, small and mid-cap stocks outperformed, with over 3,700 stocks rising, and several sectors like AI models and new consumption gaining significant attention from investors [1][7] Group 2 - The military, pharmaceutical, and photovoltaic sectors led the gains on the last trading day of June, with notable stocks like Changcheng Military Industry and Huaren Health showing significant price movements [2][3] - The white wine sector experienced a notable surge, with stocks like JiuGuiJiu and SheDeJiuYe rising by 6.88% and 3.48% respectively, reflecting renewed investor interest [4][3] - The brain-computer interface sector also saw active trading, with a 5.17% increase in the sector, driven by developments from Neuralink and its ongoing clinical trials [5][6] Group 3 - The first half of 2023 saw major indices like the North Star 50 Index rising by 39.45%, indicating a strong market recovery [7] - Key sectors that attracted investment included AI models, humanoid robots, new consumption, innovative drugs, and solid-state batteries, with significant gains observed across these areas [7][8] - Structural opportunities are expected to dominate the upcoming earnings season, with a shift in active funds from pharmaceuticals and consumption towards technology and finance sectors [8]